Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Two die and thousands homeless after flooding hits Russia's Dagestan - 2Medtronic has 'significant firepower' for multiple acquisitions, executives say
- 3French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- 4Renewables cover over 50% of German electricity consumption in Q1
- 5The Best 20 Photography Instagram Records to Follow
- The Benefits of Rehearsing Careful Nurturing
- Two UN peacekeepers killed in explosion in Lebanon
- Extremely Rare Snub-Nosed Monkey Was Just Born for the First Time Outside of Asia
- Top 10 Arising Advances That Will Shape What's in store
- Heavy rain, floods kill at least 45 people in Afghanistan, Pakistan
- Golden Globes 2026 full nominations list: 'One Battle After Another' and 'The White Lotus' lead in film and television categories
- NASA is shooting for the moon. A guide to the Artemis II mission
- A definitive Manual for 2024's Most In vogue Wedding Dresses
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
